Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).
- Conditions
- Asthma
- Interventions
- Registration Number
- NCT01396278
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The aim of the study is to assess and compare efficacy and safety of BI 54903 at three different dosages (b.i.d)., fluticasone propionate hydrofluoroalkane (HFA) metered dose inhaler (MDI) at a dose of 440 mcg b.i.d and low dose fluticasone propionate 88 mcg b.i.d. over an 8-week treatment period in asthmatic patients aged 12 to 65 years inadequately controlled medium dose ICS therapy as demonstrated by a decrease in forced expiratory volume in one second (FEV1) range 10 to 25 % and an asthma control questionnaire-6 (ACQ-6) equal or greater than 1.5 at time of randomisation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 9
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description BI 54903 medium dose BI 54903 Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI BI 54903 high dose BI 54903 Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI BI 54903 low dose BI 54903 patient to receive Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoroalkane (HFA) metered dose inhaler (MDI) BI 54903 medium dose Placebo Respimat inhaler containing medium dose BI 54903 plus placebo matching HFA MDI BI 54903 low dose Placebo patient to receive Respimat inhaler containing low dose BI 54903 plus placebo matching hydrofluoroalkane (HFA) metered dose inhaler (MDI) BI 54903 high dose Placebo Respimat inhaler containing high dose BI 54903 plus placebo matching HFA MDI Fluticasone propionate 440 mcg BID Fluticasone propionate Fluticasone HFA MDI containing 440 mcg ICS plus placebo matching Respimat inhaler Fluticasone propionate 88 mcg BID Fluticasone propionate Fluticasone HFA MDI containing 88 mcg ICS plus placebo matching Respimat inhaler
- Primary Outcome Measures
Name Time Method Mean Change From Randomisation Baseline to the End of the 8-week Treatment Period in Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Forced Expiratory Volume in One Second (FEV1) At baseline and week 8 Mean change from randomisation baseline to the end of the 8-week treatment period in trough (morning pre-dose and pre-rescue bronchodilator) Forced expiratory volume in one second (FEV1).
- Secondary Outcome Measures
Name Time Method Mean Changes From Randomization Baseline in Trough (Morning Pre-dose and Pre-rescue Bronchodilator) Forced Vital Capacity (FVC) After 2, 4 and 8-week Treatment Periods At baseline and week 2, 4, 8. Mean changes from randomization baseline in trough (morning pre-dose and pre-rescue bronchodilator) forced vital capacity (FVC) after 2, 4 and 8-week treatment periods.
Mean Changes From Randomization Baseline in Trough (Morning Pre-dose and Pre-rescue Bronchodilator) FEV1 After 2 and 4-week Treatment Periods At baseline and week 2 and 4. Mean changes from randomization baseline in trough (morning pre-dose and pre-rescue bronchodilator) FEV1 after 2 and 4-week treatment periods.
Mean Pre-dose (and Pre-rescue) Peak Expiratory Flow (PEF) as Assessed Via Asthma Monitor2+ (AM2+) in the Morning and Evening of the Last Week of the 8-week Treatment Period At week 8. Mean pre-dose (and pre-rescue) peak expiratory flow (PEF) as assessed via Asthma Monitor2+ (AM2+) in the morning and evening of the last week of the 8-week treatment period.
Mean Rescue Medication Use (Daytime and Night-time) as Assessed Via AM2+ in the Morning and Evening of the Last Week of the 8-week Treatment Period At week 8. Mean rescue medication use (daytime and night-time) as assessed via AM2+ in the morning and evening of the last week of the 8-week treatment period.
Mean Change From Randomisation Baseline in ACQ-6 Scores at Subsequent Study Visits At baseline and week 2, 4, 8. The Asthma Control Questionnaire (ACQ) consists of 6 patient self-evaluated questions with each question in 7-point scale. The items are equally weighted and the ACQ score is the mean of 6 items and ranges between 0 (well controlled) and 6 (extremely poorly controlled). Mean scores of less than or equal to 0.75 indicate well-controlled asthma, scores between 0.76 and less than 1.5 indicate partly controlled asthma, and a score greater than or equal to 1.5 indicates uncontrolled asthma.
Mean Change From Randomisation Baseline in Asthma Quality of Life Questionnaire (AQLQ(S)+12) Scores at Subsequent Study Visits At baseline and week 2, 4, 8. AQLQ(S)+12 are well established and validated questionnaires to measure control of asthma symptoms and quality of life, which is a patient-reported self-administered outcome questionnaire containing 32 items. Each item is scored on a 7-point scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time to Withdrawal Due to First Asthma Exacerbation At week 8. Time to withdrawal due to first asthma exacerbation.
Mean Change From Randomization Baseline in Through (Morning Pre-dose and Pre-rescue Bronchodilator) FEF 25-75 After 2, 4 and 8-week Treatment Periods At baseline and week 2, 4 and 8. Mean change from randomization baseline in through (morning pre-dose and pre-rescue bronchodilator) Forced expiratory flow between 25% and 75% of vital capacity (FEF 25-75) after 2, 4 and 8-week treatment periods.
Trial Locations
- Locations (37)
1248.7.01035 Boehringer Ingelheim Investigational Site
🇺🇸Aventura, Florida, United States
1248.7.01056 Boehringer Ingelheim Investigational Site
🇺🇸Rolla, Missouri, United States
1248.7.01013 Boehringer Ingelheim Investigational Site
🇺🇸Philadelphia, Pennsylvania, United States
1248.7.01047 Boehringer Ingelheim Investigational Site
🇺🇸Fountain Valley, California, United States
1248.7.01044 Boehringer Ingelheim Investigational Site
🇺🇸Stockton, California, United States
1248.7.01023 Boehringer Ingelheim Investigational Site
🇺🇸Fullerton, California, United States
1248.7.01028 Boehringer Ingelheim Investigational Site
🇺🇸Palmdale, California, United States
1248.7.01055 Boehringer Ingelheim Investigational Site
🇺🇸Oak Lawn, Illinois, United States
1248.7.01019 Boehringer Ingelheim Investigational Site
🇺🇸Baltimore, Maryland, United States
1248.7.01011 Boehringer Ingelheim Investigational Site
🇺🇸Eagle, Idaho, United States
1248.7.01053 Boehringer Ingelheim Investigational Site
🇺🇸Alexandria, Virginia, United States
1248.7.01022 Boehringer Ingelheim Investigational Site
🇺🇸Miami, Florida, United States
1248.7.01015 Boehringer Ingelheim Investigational Site
🇺🇸Centennial, Colorado, United States
1248.7.01021 Boehringer Ingelheim Investigational Site
🇺🇸Portland, Oregon, United States
1248.7.01039 Boehringer Ingelheim Investigational Site
🇺🇸North Dartmouth, Massachusetts, United States
1248.7.01026 Boehringer Ingelheim Investigational Site
🇺🇸Ocean City, New Jersey, United States
1248.7.01054 Boehringer Ingelheim Investigational Site
🇺🇸Trenton, New Jersey, United States
1248.7.01045 Boehringer Ingelheim Investigational Site
🇺🇸Cincinnati, Ohio, United States
1248.7.01050 Boehringer Ingelheim Investigational Site
🇺🇸Austin, Texas, United States
1248.7.01012 Boehringer Ingelheim Investigational Site
🇺🇸Upland, Pennsylvania, United States
1248.7.01002 Boehringer Ingelheim Investigational Site
🇺🇸Live Oak, Texas, United States
1248.7.01025 Boehringer Ingelheim Investigational Site
🇺🇸Murray, Utah, United States
1248.7.01036 Boehringer Ingelheim Investigational Site
🇺🇸Warrensburg, Missouri, United States
1248.7.01051 Boehringer Ingelheim Investigational Site
🇺🇸Columbus, Georgia, United States
1248.7.01040 Boehringer Ingelheim Investigational Site
🇺🇸Pittsburgh, Pennsylvania, United States
1248.7.01046 Boehringer Ingelheim Investigational Site
🇺🇸San Antonio, Texas, United States
1248.7.01038 Boehringer Ingelheim Investigational Site
🇺🇸Long Beach, California, United States
1248.7.01052 Boehringer Ingelheim Investigational Site
🇺🇸Savannah, Georgia, United States
1248.7.01004 Boehringer Ingelheim Investigational Site
🇺🇸Mission Viejo, California, United States
1248.7.01037 Boehringer Ingelheim Investigational Site
🇺🇸Ypsilanti, Michigan, United States
1248.7.01049 Boehringer Ingelheim Investigational Site
🇺🇸Berlin, New Jersey, United States
1248.7.01020 Boehringer Ingelheim Investigational Site
🇺🇸Omaha, Nebraska, United States
1248.7.01048 Boehringer Ingelheim Investigational Site
🇺🇸Charleston, South Carolina, United States
1248.7.01031 Boehringer Ingelheim Investigational Site
🇺🇸High Point, North Carolina, United States
1248.7.01032 Boehringer Ingelheim Investigational Site
🇺🇸San Antonio, Texas, United States
1248.7.01001 Boehringer Ingelheim Investigational Site
🇺🇸Waco, Texas, United States
1248.7.01030 Boehringer Ingelheim Investigational Site
🇺🇸Tacoma, Washington, United States